Laboratorios Lesvi, S.L.
Records under this name other than the patents Laboratorios Lesvi, S.L. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Laboratorios Lesvi, S.L.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,962,018 | Oral Formulation of Anhydrous Olanzapine Form I Formerly held In force · High confidence | In force | High confidence | |
| US 8,455,655 | Preparation of dihydropyridines Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,927,743 | Process for Obtaining Dronedarone Formerly held In force · High confidence | In force | High confidence | |
| US 9,505,771 | Stable micronised monoclin form of asenapine maleate and its synthesis Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,533,994 | Monoclinic crystalline form of asenapine maleate with a specific particle size distribution Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,309,186 | Polymorphic form of a long-acting beta-2 adrenoceptor agonist Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,131,630 | Process for preparing (3RS)-3-[(2SR)-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,888,500 | Particle size stabilization process Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,653,280 | Process for the preparation of asenapine Formerly held Lapsed on the fee record Ended Feb 18, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 18, 2026 | USPTO record |
| US 9,623,010 | Orodispersible tablets Formerly held Lapsed on the fee record Ended Apr 18, 2025 · USPTO record | Lapsed on the fee record | Ended Apr 18, 2025 | USPTO record |